Home | coming soon

top of page

ROADS CLINICAL STUDY for PATIENTS WITH NEWLY DIAGNOSED METASTATIC BRAIN TUMORS | REFER A PATIENT

Why Participate?
Radiation Treatments
Participating Hospitals
FAQs
Contact
Home
Items

Use tab to navigate through the menu items.

The ROADS Study is sponsored by GT Medical Technologies, Inc., the makers of GammaTile Therapy®. Please discuss the

risks and benefits of participating in this clinical study with your care team.

Indications

GammaTile Therapy is indicated to deliver radiation therapy in patients with newly diagnosed malignant and recurrent brain tumors. Possible complications can occur with any neurosurgical procedure and include cerebrospinal fluid leaks, infection, delayed hemorrhage, and adhesion formation. For full product and safety information, speak to your physician and refer to the instructions for use.

Why Participate?
Radiation Treatments
Participating Hospitals
FAQs
Contact
Home
Items
More

Use tab to navigate through the menu items.

ROADS CLINICAL STUDY for PATIENTS WITH NEWLY DIAGNOSED METASTATIC BRAIN TUMORS

ENROLLING NOW

©2022 GT Medical Technologies, Inc. I All rights reserved I GammaTile is a registered trademark of GT Medical Technologies, Inc.

bottom of page